Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ME-143 · 1 trial · 1 indication
Patients will be administered ME-143 IV infusions weekly and assessed by physical exam, vital signs, hematology and clinical chemistry, urinalysis and pharmacokinetic sampling.
| Arm | Type | Description |
|---|---|---|
| single arm | EXPERIMENTAL | dose escalation |
| Name | Type | Description |
|---|---|---|
| ME-143 | DRUG | experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal. Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal. |
Inclusion Criteria: * Provision of informed consent * Male or female ≥18 years of age * Histologic or cytologic confirmed locally advanced or metastatic cancer that has no standard therapeutic alternatives. * ECOG Performance status 0-1 * A minimum life expectancy of 12 weeks * Adequate bone marrow...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
ME-143 is an investigational small molecule being developed for the treatment of solid tumors. It is currently in Phase 1 clinical development, having completed a single trial in patients with refractory solid tumors. The drug is not yet approved and remains under investigation for its safety and pharmacokinetics.
ME-143 is being developed by Lite Strategy, Inc., a company traded under the ticker LITS. The company is conducting clinical research on this small molecule for oncology indications, specifically solid tumors.
ME-143 is in Phase 1 clinical development. A Phase 1 dose escalation study has been completed, evaluating the safety and pharmacokinetics of ME-143 as a single agent in patients with refractory solid tumors. The drug is investigational and not yet approved.
ME-143 has one completed clinical trial, NCT01401868, titled 'Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors.' This trial enrolled 18 participants in the United States and was an uncontrolled, open-label study.
ME-143 is a small molecule therapeutic. It is being developed as an oncology treatment for solid tumors and is currently in Phase 1 clinical trials. The completed study evaluated its safety and pharmacokinetics in patients with refractory solid tumors.